Any current/future capex/capital investment/strategic investment?

Suven Life Sciences is constructing an additional block to accommodate new requirements for high potency compounds. The planned capital expenditure (CAPEX) for this expansion is approximately Rs. 120 crore. As of the date of the call, around Rs. 25-30 crore has already been spent with orders placed and equipment arriving. The bulk of this CAPEX will be incurred over the next two quarters, with some spillover into the next financial year. Total CAPEX for FY18 is expected to be around Rs. 90-100 crore. For FY19, a similar range of CAPEX is anticipated, including maintenance and spillover costs o

Future growth expectations in sales/revenue/volumes?

Suven Life Sciences expects overall topline growth of 5% to 10% for the next 6 months and potentially beyond. CRAMS (Contract Research and Manufacturing Services) business is expected to grow by around 10%, compensating for the decline in Specialty Chemicals. Specialty Chemicals segment is anticipated to see a 20%-25% de-growth for FY18 due to generic competition, stabilizing post this decline. Repeat business (commercial launches) guidance is around Rs. 70 crore for FY18, with a possibility of increase by Rs. 10-15 crore. Patient enrollment for Phase-2 clinical trials is progressing, with com

Future growth expectations in earnings/operating earnings/profits/EPS?

Suven Life Sciences expects overall topline growth of 5% to 10% in the next 6 months. Bottom-line (profit) growth is guided at up to 20% over the same period. EBITDA margins are expected around 35% for FY18. Core CRAMS segment EBITDA margins projected above 30%, potentially around 39% for the half year. Specialty Chemicals segment is expected to decline by 20-25% in FY18 due to generic competition but will stabilize thereafter. Repeat orders (commercial launches) are projected around Rs. 70 crore for FY18, with potential to increase slightly. The company anticipates improved product mix and in

Current/ Expected Orderbook/ Pending Orders?

Current orderbook details are not explicitly specified in the transcript. Pending orders: Mentioned a pending order of about Rs. 30 crore related to commercial launches (Page 8). Repeat orders for FY18 expected around Rs. 70 crore, with a possibility to increase by Rs. 10-15 crore (Page 5). CRAMS revenue for the quarter is Rs. 91.7 crore, including Rs. 16 crore from repeat orders (Page 10, 7). Specialty Chemicals de-growth expected at 20-25% for the full year, leading to lower orders in this segment (Page 2, 7). The company anticipates 5%-10% topline growth overall in FY18, indicatin

Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the provided transcript. The management did not discuss raising capital via debt or equity during the call. They highlighted ongoing investments in CAPEX (~Rs. 100 crore for FY18 and similar for FY19) funded through operational means. The focus remains on progressing clinical trials and business growth without reference to external fundraising. Any future financing needs were not addressed or indicated in this transcript.

IN US

Sale is live|00:00:00left today

Suven Life Sciences LtdQ3 FY17Healthcare Services

Suven Life Sciences Ltd Q3 FY17 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹268Market Cap: ₹5.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→Suven Life Sciences expects overall topline growth of 5% to 10% for the next 6 months and potentially beyond.
→CRAMS (Contract Research and Manufacturing Services) business is expected to grow by around 10%, compensating for the decline in Specialty Chemicals.
→Specialty Chemicals segment is anticipated to see a 20%-25% de-growth for FY18 due to generic competition, stabilizing post this decline.
→Repeat business (commercial launches) guidance is around Rs. 70 crore for FY18, with a possibility of increase by Rs. 10-15 crore.
→Patient enrollment for Phase-2 clinical trials is progressing, with completion expected by late 2018 and data results by mid-2019, which may impact future growth.
→Incremental growth also anticipated from preclinical compounds moving to Phase-1 clinical trials and planned Phase-2 trials for new molecules starting next year.

Margin guidance

Category 3

→Suven Life Sciences expects overall topline growth of 5% to 10% in the next 6 months.
→Bottom-line (profit) growth is guided at up to 20% over the same period.
→EBITDA margins are expected around 35% for FY18.
→Core CRAMS segment EBITDA margins projected above 30%, potentially around 39% for the half year.
→Specialty Chemicals segment is expected to decline by 20-25% in FY18 due to generic competition but will stabilize thereafter.
→Repeat orders (commercial launches) are projected around Rs. 70 crore for FY18, with potential to increase slightly.
→The company anticipates improved product mix and increased repeat orders to drive margins and profitability.
→R&D spend expected to remain steady around Rs. 60 crore annually.
→CAPEX guidance is approximately Rs. 90-100 crore for FY18, with similar levels expected next year.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
→The management did not discuss raising capital via debt or equity during the call.
→They highlighted ongoing investments in CAPEX (~Rs. 100 crore for FY18 and similar for FY19) funded through operational means.
→The focus remains on progressing clinical trials and business growth without reference to external fundraising.
→Any future financing needs were not addressed or indicated in this transcript.

Order book

→Current orderbook details are not explicitly specified in the transcript.
→Pending orders: Mentioned a pending order of about Rs. 30 crore related to commercial launches (Page 8).
→Repeat orders for FY18 expected around Rs. 70 crore, with a possibility to increase by Rs. 10-15 crore (Page 5).
→CRAMS revenue for the quarter is Rs. 91.7 crore, including Rs. 16 crore from repeat orders (Page 10, 7).
→Specialty Chemicals de-growth expected at 20-25% for the full year, leading to lower orders in this segment (Page 2, 7).
→The company anticipates 5%-10% topline growth overall in FY18, indicating some new orders or ramp-ups compensating for declines (Page 11).

Capex plans

Yes

→Suven Life Sciences is constructing an additional block to accommodate new requirements for high potency compounds.
→The planned capital expenditure (CAPEX) for this expansion is approximately Rs. 120 crore.
→As of the date of the call, around Rs. 25-30 crore has already been spent with orders placed and equipment arriving.
→The bulk of this CAPEX will be incurred over the next two quarters, with some spillover into the next financial year.
→Total CAPEX for FY18 is expected to be around Rs. 90-100 crore.
→For FY19, a similar range of CAPEX is anticipated, including maintenance and spillover costs of Rs. 20-30 crore.
→No other specific strategic investments were mentioned in this transcript.

How does Suven Life Sciences Ltd rank vs peers in Healthcare Services?

Pro feature

1Suven Life Sciences Ltd

Rev 4Mar 3

See full Healthcare Services sector rankings

Want more stocks like Suven Life Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio